Technology ID
TAB-3597
The Use of Emetine for the Treatment of SARS-CoV-2 Infection
E-Numbers
E-157-2020-0
Lead Inventor
Southall, Noel (NCATS)
Co-Inventors
Ferrer-Alegre, Marc (NCATS)
Henderson, Mark (NCATS)
Marugan, Juan (NCATS)
Dulcey Gracia, Andreas (NCATS)
Hu, Xin (NCATS)
Applications
Therapeutics
Research Materials
Therapeutic Areas
Infectious Disease
Lead IC
NCATS
ICs
NCATS
This technology includes the clinical use of the small compound emetine for the treatment of SARS-CoV-2. Previous work has shown that emetine has antiviral properties against some DNA and RNA viruses. It is thought that the mechanism may involve blocking protein synthesis. Work has shown that emetine has potential antiviral activity in multiple tissues that may make it suitable for the treatment of COVID-19.
Commercial Applications
Further clinical work may establish emetine as a therapeutic for SARS-CoV-2.
Competitive Advantages
There are no current approved therapies for SARS-CoV-2 infection.
Licensing Contact: